跨膜蛋白CLDN18.2在癌症靶向治疗中的研究进展

近年来，以肿瘤特异性分子为靶点的靶向药物在癌症治疗中取得了振奋人心的治疗效果。但由于癌症的异质性，目前的靶向治疗只能使一部分癌症患者受益，因此寻找更广谱的肿瘤治疗靶点是当务之急。CLDN18.2限制性表达于胃黏膜上皮细胞，而且其在肿瘤组织表达量较高、分布范围广。CLDN18.2异常表达与多种癌症的发生发展关系密切。近期多项临床试验结果显示，靶向CLDN18.2的抗体IMAB362用于单独治疗或联合化学治疗药物治疗效果良好，预示着CLDN18.2在癌症靶向治疗中有巨大潜力。此文对CLDN18.2的生物学特征及其在癌症靶向治疗中的最新进展做一综述。

Research progress of transmembraneCLDN18.2 in targeted cancer therapy

In recent years, drugs targeting tumor-specific molecules have achieved exciting efficacy in cancer therapy. However, due to the heterogeneity of cancers, current targeted therapy can only benefit a limited part of cancer patients. Thus, finding more broad spectrum targets is a study priority. CLDN18.2 is restrictedly expressed in gastric epithelial cells, while highly expressed and widely distributed in tumor tissues. The abnormal expression of CLDN18.2 is closely related to the occurrence and development of various cancers. Recent clinical trials have shown that CLDN18.2 targeting antibody IMAB362 works well alone or in combination with chemotherapy, indicating great potential of CLDN18.2 for cancer targeted therapy. This article reviews the biological characteristics of CLDN18.2 and its recent research progress in cancer targeted therapy.